Current Neuro-Oncology

Volume 27 Number 24
31 August 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 24, 31 August

Burton EC, Walker E, Boris L, Reyes J, Fernandez K, Wall K, Wu J, Schmidt KT, Figg WD, Brown DA.
A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.
medRxiv [Preprint]. 2025 Aug 21:2025.08.18.25333496. doi: 10.1101/2025.08.18.25333496. PMID: 40894137.Interventional study. ˍ

Drummond KJ, Spiteri M, Cain SA, Jones J, Shaya S, Topp M, Lu T, Tobler R, Valkovic AL, Moore Z, Fatunla OE, Kriel J, Moffet JJD, McAlpine H, Rosier M, Guan H, Dimou J, Schadewaldt V, Roberts-Thomson S, McArdle D, Lui E, Voelker-Albert M, di Sanzo S, Nijagal B, Narayana VK, Mitchell CB, Vissers JHA, Grimmond S, Rosenthal MA, Palmer LM, Best SA, Freytag S, Whittle JR.
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
Nat Med. 2025 Aug 21. doi: 10.1038/s41591-025-03884-4. PMID: 40841487. Interventional study. ˍ ClinicalTrials.gov ID: NCT05577416.

Kang Z, Li S, Wang L, Chen Q, Hu W, Lei T, Mao Y, Zhang J, Xiang X, Wang Q, He Z, Sun T, Wang Y, Huang M, Zhang R, Chen F, Li W.
SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study.
Ann Clin Transl Neurol. 2025 Aug 22. doi: 10.1002/acn3.70166. PMID: 40847460. Interventional study. ˍ ChiCTR.org.cn ID: ChiCTR2100045380.

Kawabata S, Goto H, Narita Y, Furuse M, Nonoguchi N, Shidoh-Kazuki R, Eza K, Hirose K, Ohno M, Kondo N, Suzuki M, Tanaka H, Ono K, Nihei K, Wanibuchi M, Miyatake SI.
Extended follow-up of recurrent glioblastoma patients treated with boron neutron capture therapy (BNCT): Long-term survival from a Phase II trial (JG002) using Cyclotron Neutron Source and Boronophenylalanine.
Appl Radiat Isot. 2025 Aug 22;226:112118. doi: 10.1016/j.apradiso.2025.112118. PMID: 40865370. Interventional study˰ ˍ

Maffezzini M, Musio S, Di Ianni N, Rumolo A, Patanè M, Galluzzo A, Sambruni I, Berlendis A, Aquino D, Baso G, Zingarelli M, Facciolla M, Maddaloni L, Valentino R, Paterra R, Agistri F, Farinotti M, Mattei L, Coluccia P, Acerbi F, DiMeco F, Pollo B, Silvani A, Eoli M, Traversari C, Montagna D, Pellegatta S.
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy.
Nat Commun. 2025 Aug 25;16(1):7279. doi: 10.1038/s41467-025-62263-2. PMID: 40855052. Translational study. ˍ

Xuexue B, Chengrui Y, Ma W, Ming F, Chao W.
Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study.
Front Oncol. 2025 Aug 25;15:1634892. doi: 10.3389/fonc.2025.1634892. PMID: 40927528. Observational study. ˍ

Daftari M, Ramsoomair CK, Aaronson D, Seetharam D, Andreae EA, Wright L, Han S, Chandar J, Lu V, Govindarajan V, Ivan ME, Komotar RJ, de la Fuente M, Shah AH.
Synergistic Treatment with Antiretrovirals and Laser Interstitial Thermal ThErapy (STARLITE) for unresectable glioblastoma: A phase 1 study protocol.
PLoS One. 2025 Aug 28;20(8):e0328204. doi: 10.1371/journal.pone.0328204. PMID: 40875628. Interventional study protocol. ˍ

Rawal KN, Degorre C, Tofilon PJ.
Glioblastoma Cells Induce Neuron Loss In Vivo and In Vitro.
Cancers (Basel). 2025 Aug 28;17(17):2817. doi: 10.3390/cancers17172817. PMID: 40940913. Lab investigation. ˍ

Lee A, Cole BL, Ojemann J, Kittle D, Perry J, Parrish-Novak J, Miller DM, Hansen S, Harrington K, Ishak L, Gombotz C, Starr K, Poliachik SL, Leary SES.
Phase 1 and expanded imaging study of tozuleristide in patients with pediatric primary central nervous system tumors.
J Neurosurg Pediatr. 2025 Aug 29:1-11. doi: 10.3171/2025.5.PEDS24630. PMID: 40882241. Interventional study˰ ˍ

Hellmold D, Johanning L, Clüver J, Holler J, Schröder NO, Bayler F, Ahmeti H, Kubelt-Kwamin C, Wieker S, Helmers AK, Synowitz M, Held-Feindt J.
Effect of focused ultrasound-induced mechanical ablation on stemness and dormancy properties of residual/peri-focally localized glioblastoma cells.
Neurooncol Adv. 2025 Aug 30;7(1):vdaf184. doi: 10.1093/noajnl/vdaf184. PMID: 40980444. Lab investigation. ˍ